logo-loader
Rolls-Royce Holdings PLC

Rolls-Royce has good exposure to booming oil and gas markets, says Goldman

oil_and_gas_prices_350_4f72f9d2d0406.jpg

US broker Goldman Sachs has kept aero engine giant Rolls-Royce (LON:RR) on its conviction buy list, suggesting the market is underestimating the strength of the oil and gas market. 

Goldman said its earnings estimates for 2012 and 2013 were 5 per cent and ten per cent ahead of the market consensus, reflecting its more bullish stance on the prospects in marine and energy and also for the recent Tognum acquisition.

The broker adds it is very bullish on Rolls–Royce’s exposure to the oil and gas capital expenditure cycle, where its oil and gas analysts expect the next 3-5 years to see the highest amount of new field development since the 1970s.

For 2011-2015, it forecasts new offshore oil and gas to grow by 20 per cent a year compound, with onshore O&G starts seeing a CAGR of 12 per cent.

Goldman also expects the recent acquisition of Tognum to produce underlying profits of €434 million in 2013, 19 per cent ahead of consensus estimates.

The broker has upgraded its share price target to 1050 pence from 1010p, based on a target 2014 estimated clean earnings multiple of 15 times and EV/EBITA of 12x. 

This gives an implied valuation of 1143p, which Goldman discounts back by one year to give its price target.

Quick facts: Rolls-Royce Holdings PLC

Price: £8.10

Market: LSE
Market Cap: £15.55 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: hVIVO PLC's 2020 pipeline 'looking strong' as it expands...

hVIVO PLC's (LON:HVO) executive chairman Trevor Phillips tells Proactive London's Andrew Scott the business is now better positioned to be profitable next year. The creator of pioneering human disease models based upon viral challenge generated revenues of £5.9mln in the six months ended June...

4 hours, 55 minutes ago

RNS

Total Voting Rights

7 hours, 57 minutes ago

Additional Listing

3 days, 4 hours ago

Director/PDMR Shareholding

1 week, 2 days ago

Director/PDMR Shareholding

1 week, 6 days ago

Holding(s) in Company

2 weeks, 2 days ago

Total Voting Rights

2 weeks, 6 days ago

2 min read